On this episode of Fortune’s Leadership Next podcast, host Diane Brady talks to Eli Lilly chair ... with the scientific team ...

So far this year, Eli Lilly (NYSE: LLY) has been on an absolute tear and is swiftly becoming the world's most prolific ...

In all likelihood, when the management team at Eli Lilly and Company announces financial results for the third quarter of the 2024 fiscal year, that growth will be considered rather significant.

Operator Ladies and gentlemen, thank you for standing by and welcome to the Lilly Q3 2024 earnings call. [Operator ...

Another issue for investors is that Eli Lilly adjusted its guidance for the year, now projecting its adjusted EPS to fall ...

Even a juggernaut like Eli Lilly (NYSE: LLY) can miss the mark sometimes. When it reported its third-quarter earnings on Oct. 30, its share price plunged to the tune of 11% before recovering somewhat, ...

Almost all cases of ALS and half of frontotemporal dementia (FTD) cases are linked to dysfunction in a protein TDP-43.

In addition to top-line figures that missed Wall Street expectations, management ... team just identified what they believe are the 10 best stocks for investors to buy now… and Eli Lilly wasn ...

Eli Lilly's weight loss drug sales in Q3 weren ... at least temporarily. In the Q3 report, management trimmed its guidance for 2024's revenue to a maximum of $46 billion, just three months after ...

Regular meetings with company management allow the team to ... for roughly 10% of the strategy’s assets. The team remains bullish on Eli Lilly's leadership in the weight-loss market and believes ...

Eli Lilly (NYSE: LLY) and Novo Nordisk (NYSE: NVO), the kings of the titanic weight-loss drugs market, might have a problem on their hands. After reporting their third-quarter earnings, shares of ...

Despite the above, there are still a couple of silver linings that provide more than enough reason to be bullish about this stock.